The report named “Spanish Participation in the Innovative Medicines Initiative (IMI)” has been recently published by the Center for Industrial Technological Development (CDTI). This report lists the main indicators of participation in 8 of the 11 IMI’s calls supported under the 7th Framework Programme.
In the third edition of the Fellowship in Liver Transplant Surgery, Astellas Pharma has exclusively chosen the Liver Surgery and Transplantation Unit at the Hospital Clínic de Barcelona to train a specialist in this field. This year, Dr. Rocío García Pérez, a specialist in General and Digestive Surgery, has been awarded with the fellowship. Dr. Pérez started her formation on May 15th at the department led by Dr. Juan Carlos García-Valdecasas.
In the context of the Graphene Week 2014, the European Commission announced that the Graphene Flagship, one of the largest European research initiatives, is doubling its size and now includes more than 140 organizations from 23 countries. IDIBAPS is one of new 66 partners of the consortium through the team of Maria Victoria Sánchez-Vives, MD, PhD, ICREA Research Professor and team leader of the IDIBAPS group Systems Neuroscience. Professor Sanchez-Vives joins the Neurographene project, coordinated by Rosa Villa, PhD, from the CIBER-BBN Biomonitoring Group at the Barcelona Microelectronics Institute (IMB-CNM), and whose aim is to validate graphene as a brain interface material and to develop devices for both recording neural activity and for brain stimulation. The other partner in this project is the Austrian company Guger Technologies.
Efficacy results from the comparison between the use of insulin pumps and multiple injections (OpT2mise trial) could define how this treatment can help in the management of insulin-requiring Type 2 Diabetes. Data obtained after six months show that patients who used the pump therapy safely achieved better glucose control, with 20% less insulin and without significant differences in weight gain.
In recent years, cancer research has been focused on the identification of mutations in genes involved in tumor development. Nevertheless, the molecular pathways that contribute to the progression of the disease remain quite unknown. The journal Nature publishes a paper in which an international team of scientists, led by Nabeel Bardesy, PhD, from the Harvard Medical School, suggests that a mutation in the IDH enzyme (isocitrate dehydrogenase), that occurs in liver progenitor cells, promotes the progression of cholangiocarcinoma, a type of liver cancer. Josep M. Llovet, MD, PhD, ICREA Research Professor at the HCC Translational Research Lab of the Liver Unit at IDIBAPS and Director of Mount Sinai Liver Cancer Program at the Icahn School of Medicine at Mount Sinai (New York) has collaborated in the study together with Daniela Sia, PhD, and Helena Cornellà, members of the same research group.
A group of researchers led by professor Carles Enrich, Chief of IDIBAPS‘ Endocytosis and Protein Intracellular Transit team and member of Cellular Biology, Immunology and Neurosciences UB Dept., have found that cholesterol plays a key role in cell mobility and tissue invasion. The results of the study prove that the accumulation of LDL cholesterol cells —the one carried by low-density lipoproteins— may play a crucial role in promoting cell mobility. On the contrary, high levels of HDL cholesterol —the one carried by high-density lipoproteins— may avoid cell propagation. This is a key study to better understand cancer metastasis, the process in which cancer cells invade healthy tissues, and foster the discussion on the relationship between cholesterol levels and cancer incidence. The paper is published in open access Cell Reports.